Published: Wed, February 03, 2021

AstraZeneca vaccine is shown to significantly reduce transmission of COVID-19

AstraZeneca vaccine is shown to significantly reduce transmission of COVID-19

Prof Andrew Pollard, from the Oxford Vaccine Trial, said: "These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA and EMA to grant the vaccine emergency use authorisation".

If there is no virus then they can not spread it.

"It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation for a 12-week prime-boost interval, as they look for the optimal approach to rollout".

The company said based on the 20,000 participants who were enrolled across four clinical trials in the UK, Brazil and South Africa, the vaccine was well tolerated and that there were no serious safety events.

Instead, the dosing mishap was presented to the trial participants in a letter dated June 8 as an opportunity for University of Oxford researchers to learn how well the vaccine works at different doses.

Moreover, for those who received a second standard dose of vaccine at 12 or more weeks after the first dose, vaccine efficacy was 82.4% (95% CI 62.7%-91.7%).


The researchers hope to report data regarding the new variants in the coming days, and expect the findings to be broadly similar to those already reported by fellow vaccine developers.

In authorizing the vaccine, United Kingdom regulator accepted the pooled results, but didn't approve administering the half-dose/full-dose regimen. The study has not been peer-reviewed yet, but it was greeted with excitement by British officials under pressure to justify their decision to delay the second dose.

The countries of the European Union are going to be months behind, even if they sort out their problems with vaccine supply very soon.

Pollard and colleagues found vaccine efficacy was 54.9% (95% CI 32.7%-69.7%) at less than 6 weeks, and was supported by data showing binding antibody responses more than two-fold higher after 12 or more weeks versus an interval of less than 6 weeks in adults ages 18-55.

Tuesday's conditional backing for the vaccine comes days after President Emmanuel Macron told reporters that the vaccine was "quasi ineffective for people over 65". The vaccine has received a green light for use in India and elsewhere, including in Europe, but has hit manufacturing shortfalls in Europe.

Overall vaccine efficacy was 66.7% (95% CI 57.4%-74.0%) more than 14 days after the second dose, which included the low-dose/standard dose groups and standard-dose/standard-dose groups. The jab has come under scrutiny because of the dosing error in the Oxford trial and a paucity of data about its efficacy in older people who are most vulnerable to the virus.

Like this: